• Joao P. De AquinoEmail author
  • Bachaar Arnaout


As legislation and societal perception surrounding the use of cannabinoids rapidly change, addiction specialists need to be knowledgeable about cannabinoid psychopharmacology, so that they can adequately inform patients, other healthcare providers, and policy decision-makers. This chapter provides a brief review of the effects of plant-based and synthetic cannabinoids, focusing on their time- and dose-dependent effects on mood, anxiety, perception, cognition, and psychomotor functioning. We also discuss risk factors for the progression to cannabis use disorder (CUD), and pharmacological and psychosocial treatments for CUD. Finally, the chapter covers the effects of cannabinoids on individuals with psychiatric disorders, medicinal use of cannabinoids, and potential pharmacokinetic interactions with other psychotropic medications.


Cannabis cannabinoids marijuana cannabis use disorder cannabinoid psychopharmacology 


  1. 1.
    Ahrnsbrak R, Bose J, Hedden S, Lipari R, Park-Lee E. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.Google Scholar
  2. 2.
    Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the future National Survey Results on Drug Use, 1975–2016: overview, key findings on adolescent drug use. Institute for Social Research; 2017.Google Scholar
  3. 3.
    Azofeifa A. National estimates of marijuana use and related indicators—National Survey on Drug Use and Health, United States, 2002–2014. MMWR Surveill Summ. 2016;65:1.CrossRefGoogle Scholar
  4. 4.
    Rey AA, Purrio M, Viveros MP, Lutz B. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology. 2012;37(12):2624–34.CrossRefGoogle Scholar
  5. 5.
    ElSohly M, Gul W. Constituents of Cannabis sativa. In: Handbook of Cannabis, vol. 3; 2014. p. 1093.Google Scholar
  6. 6.
    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79:613.CrossRefGoogle Scholar
  7. 7.
    Ranganathan M, D’souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425–44.CrossRefGoogle Scholar
  8. 8.
    Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009;23(3):266–77.CrossRefGoogle Scholar
  9. 9.
    Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry. 2008;64(11):966–73.CrossRefGoogle Scholar
  10. 10.
    Dubois S, Mullen N, Weaver B, Bedard M. The combined effects of alcohol and cannabis on driving: impact on crash risk. Forensic Sci Int. 2015;248:94–100.CrossRefGoogle Scholar
  11. 11.
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–64.CrossRefGoogle Scholar
  12. 12.
    Blanco C, Hasin DS, Wall MM, Flórez-Salamanca L, Hoertel N, Wang S, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA Psychiat. 2016;73(4):388–95.CrossRefGoogle Scholar
  13. 13.
    Bonn-Miller MO, Harris AH, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012;9(4):404–16.CrossRefGoogle Scholar
  14. 14.
    Sibley MH, Pelham WE Jr, Molina BS, Coxe S, Kipp H, Gnagy EM, et al. The role of early childhood ADHD and subsequent CD in the initiation and escalation of adolescent cigarette, alcohol, and marijuana use. J Abnorm Psychol. 2014;123(2):362.CrossRefGoogle Scholar
  15. 15.
    Bidwell L, Henry E, Willcutt E, Kinnear M, Ito T. Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students. Drug Alcohol Depend. 2014;135:88–94.CrossRefGoogle Scholar
  16. 16.
    Schierenbeck T, Riemann D, Berger M, Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381–9.CrossRefGoogle Scholar
  17. 17.
    D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35–45.CrossRefGoogle Scholar
  18. 18.
    Compton MT, editor. Marijuana and mental health: American Psychiatric Publishing; 2016.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PsychiatryYale School of MedicineNew HavenUSA

Personalised recommendations